Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVANOS MEDICAL, INC. stock logo
AVNS
AVANOS MEDICAL
$12.04
-2.5%
$11.63
$9.30
$25.36
$573.07M1.12672,525 shs515,700 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.64
-4.0%
$1.78
$1.30
$7.00
$146.14M1.622.71 million shs1.23 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$24.31
-0.7%
$28.58
$23.15
$79.88
$9.52B1.939.47 million shs8.21 million shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$18.86
$16.55
$8.15
$19.01
$532.05M2.19632,414 shs220,906 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVANOS MEDICAL, INC. stock logo
AVNS
AVANOS MEDICAL
-0.37%+3.35%+14.71%+0.29%-48.33%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-4.18%+7.00%+95.04%+29.72%-57.10%
Moderna, Inc. stock logo
MRNA
Moderna
-1.45%+1.16%-6.32%-11.82%-68.06%
ZimVie Inc. stock logo
ZIMV
ZimVie
-0.16%-0.42%+0.27%+97.90%+15.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVANOS MEDICAL, INC. stock logo
AVNS
AVANOS MEDICAL
$12.04
-2.5%
$11.63
$9.30
$25.36
$573.07M1.12672,525 shs515,700 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.64
-4.0%
$1.78
$1.30
$7.00
$146.14M1.622.71 million shs1.23 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$24.31
-0.7%
$28.58
$23.15
$79.88
$9.52B1.939.47 million shs8.21 million shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$18.86
$16.55
$8.15
$19.01
$532.05M2.19632,414 shs220,906 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVANOS MEDICAL, INC. stock logo
AVNS
AVANOS MEDICAL
-0.37%+3.35%+14.71%+0.29%-48.33%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-4.18%+7.00%+95.04%+29.72%-57.10%
Moderna, Inc. stock logo
MRNA
Moderna
-1.45%+1.16%-6.32%-11.82%-68.06%
ZimVie Inc. stock logo
ZIMV
ZimVie
-0.16%-0.42%+0.27%+97.90%+15.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
2.00
HoldN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$8.80233.33% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$42.8876.40% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
2.00
Hold$17.75-5.89% Downside

Current Analyst Ratings Breakdown

Latest INO, MRNA, AVNS, and ZIMV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$18.00 ➝ $15.00
8/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$3.00
8/12/2025
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingEqual Weight$32.00
7/31/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral$19.00
7/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$26.00 ➝ $25.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
$692.50M0.81$11.47 per share1.05$18.03 per share0.67
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$220K637.68N/AN/A$1.90 per share1.39
Moderna, Inc. stock logo
MRNA
Moderna
$3.06B3.10N/AN/A$28.33 per share0.86
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M1.18$1.85 per share10.17$13.83 per share1.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
-$392.10M-$10.07N/A6.96N/A-66.89%6.16%4.57%10/29/2025 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$2.61N/AN/AN/AN/A-163.32%-96.41%11/13/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$25.83M-$0.70N/AN/A-4.39%6.37%3.34%10/29/2025 (Estimated)

Latest INO, MRNA, AVNS, and ZIMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.63-$0.61+$0.02-$0.61$0.01 millionN/A
8/5/2025Q2 2025
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
$0.18$0.17-$0.01-$1.66$165.50 million$175.00 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/30/2025Q2 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.2080$0.26+$0.0520-$0.14$112.60 million$116.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
0.12
2.64
1.58
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.66
1.66
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
ZimVie Inc. stock logo
ZIMV
ZimVie
0.56
2.37
1.60

Institutional Ownership

CompanyInstitutional Ownership
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
95.17%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
2.64%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
ZimVie Inc. stock logo
ZIMV
ZimVie
5.41%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avanos Medical, Inc. stock logo
AVNS
Avanos Medical
2,22746.40 million45.18 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32053.14 million51.92 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
1,77028.21 million26.69 millionOptionable

Recent News About These Companies

Hsbc Holdings PLC Buys New Shares in ZimVie Inc. $ZIMV
Ancora Advisors LLC Raises Position in ZimVie Inc. $ZIMV
Ariel Investments LLC Boosts Stake in ZimVie Inc. $ZIMV
ZimVie (NASDAQ:ZIMV) Sets New 1-Year High - What's Next?
Nuveen LLC Buys New Shares in ZimVie Inc. $ZIMV
ZimVie Reports Second Quarter 2025 Financial Results
Insights into ZimVie's Upcoming Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AVANOS MEDICAL stock logo

AVANOS MEDICAL NYSE:AVNS

$12.04 -0.31 (-2.49%)
Closing price 03:59 PM Eastern
Extended Trading
$12.02 -0.02 (-0.19%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.64 -0.11 (-4.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.63 -0.01 (-0.38%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$24.31 -0.16 (-0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$24.34 +0.03 (+0.10%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$18.86 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$18.86 0.00 (0.00%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.